Cytokinetics announced on Tuesday that its experimental drug Myqorzo significantly improved heart failure symptoms and cardiovascular fitness in patients with non-obstructive hypertrophic cardiomyopathy, a rare inherited heart disorder.
The results, detailed in a company press release, met both primary efficacy goals of the Phase 3 ACACIA clinical trial with statistical significance. Hypertrophic cardiomyopathy (HCM) is a condition characterized by abnormal thickening of the heart muscle, which can lead to heart failure and other complications.
Cytokinetics is currently in the early stages of Myqorzo’s commercial launch as a treatment for the more severe obstructive form of HCM. If the ACACIA study results are also approved by regulatory authorities, the drug could become available to a much broader patient population, including those with the non-obstructive form of the disease.
Analysts have projected that Myqorzo could achieve peak annual sales of up to $5 billion if it gains full regulatory clearance and expands its market reach.
Related articles
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
Regenxbio’s Duchenne Gene Therapy Shows Success in Trial, FDA Submission Next
Regenxbio said Thursday that its experimental gene therapy for Duchenne muscular dystrophy produced sufficiently high levels of a miniaturized muscle...
Alcohol Addiction Treatment: A Paradigm Shift in Recovery Approaches
All Jillian wanted was to regain control of her drinking. At 38, she knew alcohol had already cost her a marriage and begun to threaten her career. Wh...
Gene Therapy Viruses Linked to Rare Tumor in Young Patient: FDA Commissioner Resigns Amid Safety Concerns
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get st...
FDA Commissioner Marty Makary Resigns Amid Leadership Controversy; Eli Lilly Weight Loss Drug Trial Results Released
Good morning, everyone, and how are you today? The middle of the week has finally arrived, and you should congratulate yourselves for making it this f...
New Study Warns: Common Drug May Reduce Gene Therapy Effectiveness in Dravet Syndrome Patients
BOSTON — A medicine increasingly used to mitigate the risk of deadly gene therapy side effects could also blunt the therapy’s effectiveness, a new stu...